New combo therapy aims to halt spread of nasopharyngeal cancer
NCT ID NCT04944914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose primary tumor is under control and who have had at least one round of chemotherapy will be randomly assigned to one of two groups. The main goal is to see how long patients live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab (an immunotherapy drug) and stereotactic body radiotherapy (SBRT, a precise type of radiation)
- What this could lead to
- If successful, this could show that adding targeted radiation to immunotherapy helps control cancer spread better than immunotherapy alone, potentially improving how long patients live without their cancer getting worse.
- What could go wrong
- This is a phase 3 trial, but it is still recruiting and results are not yet known. The combination may cause more side effects than immunotherapy alone, and it is only tested in a specific group of patients with limited metastases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers